{{medical}}
{{Drugbox
| Watchedfields = changed
| verifiedrevid = 460025108
| drug_name =
| image = Ceftriaxone-skeletal.svg
| image2 = Ceftriaxone ball-and-stick.png
<!--Clinical data-->
| pronounce   = {{IPAc-en|ˌ|s|ɛ|f|t|r|aɪ|ˈ|æ|k|s|oʊ|n}}
| tradename = Rocephin, Epicephin, Wintriaxone, others
| Drugs.com = {{drugs.com|monograph|Ceftriaxone_Sodium}}
| MedlinePlus       = a685032
| licence_CA        = <!-- Health Canada may use generic or brand name (generic name preferred) -->
| licence_EU        = <!-- EMA uses INN (or special INN_EMA) -->
| DailyMedID        = Ceftriaxone
| licence_US        = <!-- FDA may use generic or brand name (generic name preferred) -->
| pregnancy_AU = B1
| pregnancy_AU_comment = <ref name="Drugs.com pregnancy">{{cite web | title=Ceftriaxone (Rocephin) Use During Pregnancy | website=Drugs.com | date=12 December 2019 | url=https://www.drugs.com/pregnancy/ceftriaxone.html | access-date=24 December 2019 | archive-date=2016-08-23 | archive-url=https://web.archive.org/web/20160823194224/https://www.drugs.com/pregnancy/ceftriaxone.html | dead-url=no }}</ref>
| pregnancy_US = B
| pregnancy_US_comment = <ref name="Drugs.com pregnancy" />
| routes_of_administration = [[靜脈注射|靜脈注射]]、[[肌肉注射|肌肉注射]]
| class = [[頭孢菌素#第三代|第三代頭孢菌素]]
| ATC_prefix = J01
| ATC_suffix = DD04

<!-- Legal status -->
| legal_AU = S4
| legal_AU_comment = 
| legal_BR =  <!-- OTC, A1, A2, A3, B1, B2, C1, C2, C3, C4, C5, D1, D2, E, F-->
| legal_BR_comment = 
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_CA_comment = 
| legal_DE = <!-- Anlage I, II, III or Unscheduled-->
| legal_DE_comment = 
| legal_NZ = <!-- Class A, B, C -->
| legal_NZ_comment = 
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM / Class A, B, C -->
| legal_UK_comment = 
| legal_US = Rx-only
| legal_US_comment = 
| legal_UN = <!-- N I, II, III, IV / P I, II, III, IV-->
| legal_UN_comment = 
| legal_status      = <!--For countries not listed above-->

<!--Pharmacokinetic data-->
| bioavailability = n/a
| metabolism = 在人體中幾乎不代謝。
| elimination_half-life = 5.8–8.7 小時
| excretion = [[腎|腎]]：33–67%<br>[[膽管|膽管]]：35–45%
<!--Identifiers-->
| IUPHAR_ligand = 5326
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 73384-59-5
| PubChem = 5479530
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01212
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4586394
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 75J73V1629
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07659
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 29007
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 161
<!--Chemical data-->
| IUPAC_name = (6''R'',7''R'')-7-{[(2''Z'')-2-(2-amino-1,3-thiazol-4-yl)->2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
| C=18 | H=18 | N=8 | O=7 | S=3
| SMILES = O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)CS\C4=N\C(=O)C(=O)NN4C)C(=O)O
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C18H18N8O7S3/c1-25-18(22-12(28)13(29)23-25)36-4-6-3-34-15-9(14(30)26(15)10(6)16(31)32)21-11(27)8(24-33-2)7-5-35-17(19)20-7/h5,9,15H,3-4H2,1-2H3,(H2,19,20)(H,21,27)(H,23,29)(H,31,32)/b24-8-/t9-,15-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = VAAUVRVFOQPIGI-SPQHTLEESA-N
}}
<!-- Definition and medical uses -->
'''頭孢曲松'''（Ceftriaxone），商品名為羅氏芬（Rocephin），是一種可用於治療如[[革蘭氏陽性菌|革蘭氏陽性菌]]及[[革蘭氏陰性菌|革蘭氏陰性菌]]等多種細菌感染的抗生素，包括[[中耳炎|中耳炎]]、[[心內膜炎|心內膜炎]]、[[腦膜炎|腦膜炎]]、[[肺炎|肺炎]]、骨關節炎、腹腔內感染、皮膚炎、[[泌尿道感染|泌尿道感染]]、[[淋病|淋病]]和[[骨盆腔發炎|骨盆腔發炎]]<ref name=AHFS2016/>。有時也會在手術前和咬傷後使用，以防止感染<ref name=AHFS2016/>。 頭孢曲松可以通過靜脈或肌肉注射<ref name=AHFS2016>{{Cite web|title = Ceftriaxone Sodium Monograph for Professionals – Drugs.com|url = https://www.drugs.com/monograph/ceftriaxone-sodium.html|website = www.drugs.com|accessdate = 2016-08-27|deadurl = no|archiveurl = https://web.archive.org/web/20160531224338/http://www.drugs.com/monograph/ceftriaxone-sodium.html|archivedate = 2016-05-31|df = }}</ref> 。

<!-- Side effects and mechanism -->
此藥常見的副作用包括注射部位疼痛和過敏反應<ref name=AHFS2016/> 。其他可能的副作用包括[[偽膜性結腸炎|偽膜性結腸炎]]、{{le|溶血性貧血|Hemolytic anemia}}、[[膽石症|膽石症]]和[[癲癇|癲癇]]<ref name=AHFS2016/> 。此藥不建議用於對[[青黴素|青黴素]]過敏的患者，但副作用較輕的患者除外<ref name=AHFS2016/> 。如採用靜脈注射方式時，不應同時從靜脈輸注[[鈣|鈣]]<ref name=AHFS2016/> 。初步證據顯示此藥用於懷孕和哺乳期間是相對安全的<ref>{{cite web|title=Ceftriaxone Pregnancy and Breastfeeding Warnings|url=https://www.drugs.com/pregnancy/ceftriaxone.html|website=www.drugs.com|accessdate=27 August 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160823194224/https://www.drugs.com/pregnancy/ceftriaxone.html|archivedate=23 August 2016|df=}}</ref>。此藥是第三代的[[頭孢菌素|頭孢菌素]]，藥理為抑制細菌[[細胞壁|細胞壁]]的製造<ref name=AHFS2016/>。

<!-- History, society, and culture -->
此藥是由[[羅氏|羅氏大藥廠]]在20世紀80年代早期所發明出來<ref>{{cite book|last1=Landau|first1=Ralph|last2=Achilladelis|first2=Basil|last3=Scriabine|first3=Alexander|title=Pharmaceutical Innovation: Revolutionizing Human Health|date=1999|publisher=Chemical Heritage Foundation|isbn=9780941901215|page=169|url=https://books.google.com/books?id=IH4lPs6S1bMC&pg=PA169|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170908213422/https://books.google.com/books?id=IH4lPs6S1bMC&pg=PA169|archivedate=2017-09-08|df=}}</ref>，並已列名[[世界衛生組織基本藥物標準清單|世界衛生組織基本藥物標準清單]]，為{{le|公衛系統|Health system}}所需最有效和最安全的藥物之一<ref name=WHO19th>{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}</ref>，目前也有其他的[[學名藥|學名藥]]<ref name=AHFS2016/> 。在已開發國家，此藥每劑的批發成本在2014年時約為0.20至2.32美元<ref>{{cite web|title=Ceftriaxone|url=http://mshpriceguide.org/en/single-drug-information/?DMFId=126&searchYear=2014|website=International Drug Price Indicator Guide|accessdate=29 August 2016|archive-date=2020-09-27|archive-url=https://web.archive.org/web/20200927164014/https://mshpriceguide.org/en/single-drug-information/?DMFId=126&searchYear=2014|dead-url=no}}</ref>；而在美國以此藥治療的療程通常費用不會超過25美元<ref>{{cite book|last1=Facep|first1=Hamilton MD Faaem Facmt|title=Tarascon Pocket Pharmacopoeia 2014 Deluxe Lab-Coat Edition|date=2013|publisher=Jones & Bartlett Publishers|isbn=9781284053999|page=75|url=https://books.google.com/books?id=BwqEAgAAQBAJ&pg=PA75|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170908213423/https://books.google.com/books?id=BwqEAgAAQBAJ&pg=PA75|archivedate=2017-09-08|df=}}</ref>。

== 臨床使用 ==
:{{Main|頭孢菌素}}
頭孢曲松經常（與[[大環內酯|大環內酯]]及／或[[氨基糖苷類抗生素|氨基糖苷類抗生素]]一起）用於治療社區感染的[[肺炎|肺炎]]。它是一種用於治療[[細菌性腦膜炎|細菌性腦膜炎]]的藥物之一。在小兒科，它普遍使用在治療4－8個星期大幼兒的[[敗血病|敗血病]]。它亦可治療[[萊姆病|萊姆病]]及[[淋病|淋病]]。

一般開始時的劑量是每天靜脈注射1g。其後每12－24小時則為1－2g（靜脈注射或肌注），按照感染的種類及嚴重性，可調校至每日4g。對於患有淋病的成年人，劑量是一次肌注250mg。治療淋病病人一般需要與[[阿奇黴素|阿奇黴素]]一併使用，並處理[[衣原體屬|衣原體屬]]。

頭孢曲松禁止使用於對[[頭孢菌素|頭孢菌素]]、[[青黴素|青黴素]]及／或[[碳青黴烯|碳青黴烯]]敏感的病人。

== 化學結構 ==
頭孢曲松是一種橙黃色的結晶粉，可溶於[[水|水]]，僅溶於[[甲醇|甲醇]]及甚少溶於[[乙醇|乙醇]]。1%的頭孢曲松溶液的[[pH值|pH值]]約為6.7。

[[甲氧基|甲氧基]][[亞胺|亞胺]]的結構能提高在於對[[革蘭氏陰性菌|革蘭氏陰性菌]]所分泌的[[β內醯胺酶|β內醯胺酶]]的穩定性。這種特別的穩定性能增加頭孢曲松對抗革蘭氏陰性菌的阻力。取代[[頭孢噻肟|頭孢噻肟]]易於[[水解|水解]]的[[乙醯|乙醯]]，頭孢曲松的一端有著代謝穩定的偶氮離子酮。

== 外部連結 ==
*[http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202119.html MedlinePlus Drug Information: Cephalosporins (systemic)] {{Wayback|url=http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/202119.html |date=20070202151102 }}
*[https://web.archive.org/web/20061017081419/https://www.rocheusa.com/products/rocephin/ 羅氏芬®的相關資料]

{{-}}
{{细胞壁破坏性抗生素}}
{{国家基本药物目录/抗微生物药}}

[[Category:頭孢菌素|Category:頭孢菌素]]
[[Category:世界卫生组织基本药物|Category:世界卫生组织基本药物]]